A £76 million research collaboration between a major UK-based pharmaceutical company and Imperial College, London was welcomed today by the Association of the British Pharmaceutical Industry (ABPI) as "a tremendously important partnership to benefit patients in Britain".
The unique research collaboration, announced today, will see a new clinical imaging centre built in west London to focus on cancer, stroke, neurological diseases such as Parkinson's and multiple sclerosis, and psychiatric diseases.
"This partnership - here seen on a unique scale - is tremendously important to not only people with these conditions but also to the reputation of the country as a world-leader in imaging technology," said Dr Trevor Jones, Director General of the ABPI.
"It is particularly appropriate that it follows hard on the heels of an ABPI survey which showed that the public see investment in medicines research as a top priority for the country and for the Government."
The survey - published yesterday (Monday) - showed that 89 per cent of people in the UK believe that pharmaceutical companies should be encouraged to invest in the UK, and that only three per cent disagreed.
GlaxoSmithKline will contribute funding of £28 million for the construction of the new Clinical Imaging Centre, next to Hammersmith Hospital. The centre will use and advance the latest technologies in magnetic resource imaging (MRI) and positron emission tomography (PET). GSK will invest a further £16 million in the latest PET and MRI imaging equipment.
For further information, please contact: ABPI Press Office 020 7747 1410